Home > Resources > Whitepapers > Exploring the Truth of Reimbursement Challenges for Cell and Gene Therapies.

Exploring the Truth of Reimbursement Challenges for Cell and Gene Therapies.

June 10, 2019

Trinity has worked with over a third of companies with cell and gene therapies (CGTs) on market or in Phase 3 clinical trials. Our work has supported business development, launch planning, evidence generation (HEOR, etc.), market access, pricing, and other critical commercial activities to support the development and launch of these therapies.1 As such, we have seen CGTs morph from a small niche into possibly the most exciting market in pharma.

Spotlight

Allied Healthcare

As one of the UK’s largest care providers and a leading healthcare provider, we understand better than most how outstanding care can make a real difference to people’s lives. We've been delivering care for over 40 years, over which time thousands of people have trusted us to look after them in their own homes. We now provide over 9 million hours of care every year - a fact we're really proud of. We’re in the unique position of being able to cater for practically all healthcare, home care and specialist needs, meaning we’re the trusted care provider of choice for many UK authorities.

OTHER WHITEPAPERS

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Small Molecule Apis Made with Compelling Science

whitePaper | July 17, 2023

As your API demand grows, we grow with you. While we can manufacture volumes in metric tons, we can also go small. If you have a chemistry-based compound and need smaller batches for clinical or commercial use, we can offer the quantities you need at our cGMP small-scale/pilot facilities until you’re ready for full-scale manufacturing.

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

The colors of life: an interdisciplinary artist-in-residence project to research fungal pigments as a gateway

whitePaper | January 10, 2022

Biological pigmentation is one of the most intriguing traits of many fungi. It holds signifcance to scientists, as a sign of biochemical metabolism and organism-environment interaction, and to artists, as the source of natural colors that capture the beauty of the microbial world.

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).